These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10669338)

  • 21. Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression.
    Papasavvas E; Sandberg JK; Rutstein R; Moore EC; Mackiewicz A; Thiel B; Pistilli M; June RR; Jordan KA; Gross R; Maino VC; Nixon DF; Montaner LJ
    J Infect Dis; 2003 Sep; 188(6):873-82. PubMed ID: 12964119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.
    Ratto-Kim S; Garner RP; Kim JH; Jagodzinski LL; Michael NL; Paris R; Redfield RR; Birx DL
    J Infect Dis; 2004 Jun; 189(11):1988-95. PubMed ID: 15143464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.
    Wit FW; van Rij RP; Weverling GJ; Lange JM; Schuitemaker H
    J Infect Dis; 2002 Dec; 186(12):1726-32. PubMed ID: 12447757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [T-cell subsets variation during clinical and immunological progression in vertically HIV-infected children].
    Resino García S; Bellón Cano JM; Navarro Caspistegui J; Gurbindo Gutiérrez D; León Leal JA; Muñoz-Fernández MA
    Medicina (B Aires); 2001; 61(5 Pt 1):557-65. PubMed ID: 11721322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantification of human immunodeficiency virus type 1 p24 antigen and antibody rivals human immunodeficiency virus type 1 RNA and CD4+ enumeration for prognosis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Read JS; Rich KC; Korelitz JJ; Mofenson LM; Harris R; Moye JH; Meyer WA; Pahwa SG; Bethel JW; Nugent RP
    Pediatr Infect Dis J; 2000 Jun; 19(6):544-51. PubMed ID: 10877171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
    Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
    An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS.
    Fletcher CV; Goodroad BK; Cummins LM; Henry K; Balfour HH; Rhame FS
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1571-4. PubMed ID: 9210687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
    J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement.
    Ledergerber B; Flepp M; Böni J; Tomasik Z; Cone RW; Lüthy R; Schüpbach J
    J Infect Dis; 2000 Apr; 181(4):1280-8. PubMed ID: 10751136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.
    Brown BK; Darden JM; Tovanabutra S; Oblander T; Frost J; Sanders-Buell E; de Souza MS; Birx DL; McCutchan FE; Polonis VR
    J Virol; 2005 May; 79(10):6089-101. PubMed ID: 15857994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virologic and host characteristics of human immunodeficiency virus type 1-infected pediatric long term survivors.
    Alexander L; Cuchura L; Simpson BJ; Andiman WA
    Pediatr Infect Dis J; 2006 Feb; 25(2):135-41. PubMed ID: 16462290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand.
    Puthanakit T; Aurpibul L; Oberdorfer P; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
    Pediatr Infect Dis J; 2007 Oct; 26(10):953-6. PubMed ID: 17901804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy.
    Fraaij PL; Verweel G; van Rossum AM; van Lochem EG; Schutten M; Weemaes CM; Hartwig NG; Burger DM; de Groot R
    Clin Infect Dis; 2005 Feb; 40(4):604-8. PubMed ID: 15712085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma.
    Furrer H; Barloggio A; Egger M; Garweg JG;
    Ophthalmology; 2003 Feb; 110(2):432-6. PubMed ID: 12578793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
    Jankelevich S; Mueller BU; Mackall CL; Smith S; Zwerski S; Wood LV; Zeichner SL; Serchuck L; Steinberg SM; Nelson RP; Sleasman JW; Nguyen BY; Pizzo PA; Yarchoan R
    J Infect Dis; 2001 Apr; 183(7):1116-20. PubMed ID: 11237839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.
    Cummins LM; Weinhold KJ; Matthews TJ; Langlois AJ; Perno CF; Condie RM; Allain JP
    Blood; 1991 Mar; 77(5):1111-7. PubMed ID: 1995097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation.
    Stiegler G; Armbruster C; Vcelar B; Stoiber H; Kunert R; Michael NL; Jagodzinski LL; Ammann C; Jäger W; Jacobson J; Vetter N; Katinger H
    AIDS; 2002 Oct; 16(15):2019-25. PubMed ID: 12370500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of HIV type 1 RNA plasma viremia, p24 antigenemia, and unintegrated DNA as viral load markers in pediatric patients.
    Bush CE; Donovan RM; Manzor O; Baxa D; Moore E; Cohen F; Saravolatz LD
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):11-5. PubMed ID: 8825613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.